NICE approves new test for spread of breast cancer.
NHS Choices, Aug 2013
http://www.nhs.uk/news/2013/08August/Pages/NICE-approves-new-test-for-spread-of-breast-cancer.aspx
Thursday, 29 August 2013
Duration of trastuzumab for HER2-positive breast cancer
Duration of trastuzumab for HER2-positive breast cancer. The lancet oncology, July 2013, Vol.14(8), p.678-79.
Montemurro, F. and Aglietta, M.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70273-0/fulltext?rss=yes
Several large randomised trials completed in the mid-2000s produced overwhelming evidence that the anti-HER2 monoclonal antibody trastuzumab, administered either concomitantly or sequentially with adjuvant chemotherapy for 12 months, increases the cure rate for women with HER2-positive operable breast cancer. One surprising aspect of this success story is that the choice of 12-month treatment duration was mostly as a result of a best guess, rather than on the basis of pre-existing evidence.
Montemurro, F. and Aglietta, M.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70273-0/fulltext?rss=yes
Several large randomised trials completed in the mid-2000s produced overwhelming evidence that the anti-HER2 monoclonal antibody trastuzumab, administered either concomitantly or sequentially with adjuvant chemotherapy for 12 months, increases the cure rate for women with HER2-positive operable breast cancer. One surprising aspect of this success story is that the choice of 12-month treatment duration was mostly as a result of a best guess, rather than on the basis of pre-existing evidence.
Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery
Predictors of recurrence for ductal carinoma in situ after breast-conserving surgery. The lancet oncology, Aug 2013, Vol.14(9), p. e348-e357.
Benson, J.R. and Wishart, G.C.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70135-9/abstract?rss=yes
Ductal carcinoma in situ (DCIS) constitutes a major public health problem, with up to half of screen-detected cancers representing pure forms of DCIS without evidence of invasion. A proportion of cases detected with routine screening would not have progressed to a life-threatening form of breast cancer during the patient's lifetime, and overdiagnosis of breast cancer is a cause for concern.
Benson, J.R. and Wishart, G.C.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70135-9/abstract?rss=yes
Ductal carcinoma in situ (DCIS) constitutes a major public health problem, with up to half of screen-detected cancers representing pure forms of DCIS without evidence of invasion. A proportion of cases detected with routine screening would not have progressed to a life-threatening form of breast cancer during the patient's lifetime, and overdiagnosis of breast cancer is a cause for concern.
Combination endocrine treatments unproven in breast cancer
Combination endocrine treatments unproven in breast cancer. The lancet oncology, Sept 2013, Vol. 14(10), p.917-18.
Buzdar, A.U.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70364-4/fulltext?_eventId=login&rss=yes
Ovarian ablation, which was introduced more than 100 years ago, was the first endocrine treatment for advanced breast cancer, followed by adrenalectomy and hypophysectomy. These ablative therapies have since been replaced by antioestrogen treatments, luteinising-hormone-releasing hormone agonists, and aromatase inhibitors.Other endocrine treatments with different mechanisms of action have also become available for breast cancer: oestrogens, progestins, androgens, antiandrogens, and selective oestrogen-receptor downregulators.
Buzdar, A.U.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70364-4/fulltext?_eventId=login&rss=yes
Ovarian ablation, which was introduced more than 100 years ago, was the first endocrine treatment for advanced breast cancer, followed by adrenalectomy and hypophysectomy. These ablative therapies have since been replaced by antioestrogen treatments, luteinising-hormone-releasing hormone agonists, and aromatase inhibitors.Other endocrine treatments with different mechanisms of action have also become available for breast cancer: oestrogens, progestins, androgens, antiandrogens, and selective oestrogen-receptor downregulators.
Subglandular breast augmentation with textured, anatomic, cohesive silicone implants
Subglandular breast augmentation with textured, anatomic, cohesive silicone implants: A review of 440 consecutive patients. Plastic and reconstructive surgery, Aug 2013, Vol. 132(2), p.295-303.
Lista, F., et al.
http://journals.lww.com/plasreconsurg/Fulltext/2013/08000/Subglandular_Breast_Augmentation_with_Textured,.11.aspx
The Allergan Style 410 implant is a textured, anatomic, highly cohesive silicone gel–filled breast implant. Despite its widespread use in both Europe and Canada, limited data exist regarding long-term outcomes. The purpose of this study was to investigate outcomes using the Style 410 implant for primary subglandular breast augmentation.
Lista, F., et al.
http://journals.lww.com/plasreconsurg/Fulltext/2013/08000/Subglandular_Breast_Augmentation_with_Textured,.11.aspx
The Allergan Style 410 implant is a textured, anatomic, highly cohesive silicone gel–filled breast implant. Despite its widespread use in both Europe and Canada, limited data exist regarding long-term outcomes. The purpose of this study was to investigate outcomes using the Style 410 implant for primary subglandular breast augmentation.
Breast reconstruction with the Bostwick Autoderm technique
Breast reconstruction with the Bostwick Autoderm technique. Plastic and reconstructive surgery, Aug 2013, Vol. 132(2), p.261-70.
Ladizinsky, D.A., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Breast_Reconstruction_with_the_Bostwick_Autoderm.6.aspx
In 1990, Bostwick presented a technique wherein excess skin in the ptotic breast provides a deepithelialized inferiorly based dermal flap at the time of mastectomy. This adjoins the inferior border of the pectoralis major muscle, creating a complete autologous vascularized pocket, which is then covered by Wise pattern skin flaps.
Ladizinsky, D.A., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Breast_Reconstruction_with_the_Bostwick_Autoderm.6.aspx
In 1990, Bostwick presented a technique wherein excess skin in the ptotic breast provides a deepithelialized inferiorly based dermal flap at the time of mastectomy. This adjoins the inferior border of the pectoralis major muscle, creating a complete autologous vascularized pocket, which is then covered by Wise pattern skin flaps.
Microvascular autologous breast reconstruction in the context of radiation therapy
Microvascular autologous breast reconstruction in the context of radiation therapy: Comparing two reconstructive algorithms. Plastic and reconstructive surgery, Aug 2013, Vol. 132(2), 251-57.
Patel, K., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Microvascular_Autologous_Breast_Reconstruction_in.1.aspx
When postmastectomy radiation therapy is anticipated, delaying autologous reconstruction prevents radiation delivery issues and radiation-induced contour irregularities. Delayed-immediate autologous breast reconstruction may allow for maintenance of the breast skin envelope as compared with delayed reconstruction with the temporary insertion of a tissue expander. The authors compared perioperative complications and revision surgery rates of comparative cohorts to determine which method is preferable.
Patel, K., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Microvascular_Autologous_Breast_Reconstruction_in.1.aspx
When postmastectomy radiation therapy is anticipated, delaying autologous reconstruction prevents radiation delivery issues and radiation-induced contour irregularities. Delayed-immediate autologous breast reconstruction may allow for maintenance of the breast skin envelope as compared with delayed reconstruction with the temporary insertion of a tissue expander. The authors compared perioperative complications and revision surgery rates of comparative cohorts to determine which method is preferable.
The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction
The timing of preoperative prophylactic low-molecular-weight heparin administration in breast reconstruction. Plastic and reconstructive surgery, Aug 2013, Vol. 132(2), p.279-84.
Keith, J.N., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/The_Timing_of_Preoperative_Prophylactic.8.aspx
Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients.
Keith, J.N., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/The_Timing_of_Preoperative_Prophylactic.8.aspx
Venous thromboembolism continues to be problematic despite increased recognition and advancements in venous thromboembolism prophylaxis. Although migration toward preoperative chemoprophylaxis increases, plastic surgeons seem reticent to adopt this practice. This study evaluates preoperative enoxaparin administration in breast reconstruction patients.
Quality-of-life outcomes between mastectomy alone and breast reconstruction
Quality-of-life outcomes between mastectomy alone and breast reconstruction: Comparison of patient- reported BREAST-Q and other health-related quality-of-life measures. Plastic and reconstructive surgery, Aug 2013, Vol. 132(2), p.201e-209e.
Eltahir, Y., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Quality_of_Life_Outcomes_between_Mastectomy_Alone.3.aspx
Published data on quality of life in women after breast reconstruction are inconsistent. This cross-sectional study evaluated the quality of life of women after successful breast reconstruction in comparison with those who underwent mastectomy alone.
Eltahir, Y., et al.
http://journals.lww.com/plasreconsurg/Abstract/2013/08000/Quality_of_Life_Outcomes_between_Mastectomy_Alone.3.aspx
Published data on quality of life in women after breast reconstruction are inconsistent. This cross-sectional study evaluated the quality of life of women after successful breast reconstruction in comparison with those who underwent mastectomy alone.
Subscribe to:
Posts (Atom)